The United States Food and Drug Administration (FDA) has granted final approval to Breckenridge Pharmaceutical Inc, a subsidiary of Towa Pharmaceutical, for its Abbreviated New Drug Application (ANDA) for Asenapine Sublingual Tablets in 5mg strength (generic for Saphris), it was reported on Monday.
The company plans to introduce this strength immediately. It previously launched the product's 2.5mg and 10mg strengths and will now market all three strengths.
The product has been developed in partnership with MSN Laboratories Private Limited.
Campanelli Named to Slayback Board of Directors
Dr. Reddy's Laboratories Launches Lansoprazole DR Orally Disintegrating Tablets in the US Market
Dr. Reddy's Laboratories Launches Capecitabine Tablets, USP in the US Market
Dr Reddy's Laboratories launches Fluphenazine Hydrochloride Tablets, USP in US antipsychotic market
Akorn Operating's Loteprednol Etabonate Ophthalmic Gel, 0.5% receives US FDA approval
Dr. Reddy's Laboratories Launches Vigabatrin Tablets, USP in the US Market
Dr. Reddy's Laboratories unveils Vigabatrin Tablets, USP in the US Market
Sandoz introduces generic Icatibant injection pre-filled syringe in US
Xspray Pharma commences study with modified formulation of HyNap-Dasa
CONTINUUS Pharmaceuticals receives USD69.3m US government contract
Sputnik V Meets Primary Endpoint of Safety in India Phase 2 Clinical Trial
Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA